Prostate cancer management: (1) An update on localised disease

Postgraduate Medical Journal

Volumn 79, Issue 936, 2003, Pages 575-580

  Bott, S R J ^a   Birtle, A J ^a   Taylor, C J ^a   Kirby, R S ^b  

^a 3rd Floor Research Laboratories   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; IODINE 125; IRIDIUM 192;

BEAM THERAPY; BRACHYTHERAPY; CANCER SCREENING; DIARRHEA; DYSURIA; ERECTILE DYSFUNCTION; HORMONAL THERAPY; HUMAN; IMPOTENCE; INCONTINENCE; LAPAROSCOPIC SURGERY; LETHARGY; MALE; PROCTITIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TREATMENT OUTCOME; TUMOR CLASSIFICATION; URETHRA STRICTURE; URINARY FREQUENCY;

ANDROGEN ANTAGONISTS; BRACHYTHERAPY; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY;

EID: 0344413054     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.936.575     Document Type: Review

References (67)

1. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992;23:211-22.
2. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16.
3. Shibata A, Whittemore AS. Re: prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 2001;93:1109-10.
4. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000;283:2975-8.
5. Walsh PC. Surgery and the reduction of mortality from prostate cancer. N Engl J Med 2002;347:839-40.
6. Han M, Partin AW, Piantadosi S, et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001;166:416-19.
7. Brawley OW. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 1997;80:1857-63.
8. British Association of Urological Surgeons. Analysis of minimum data set for urological cancers. (Chart 61, 47.) London: British Association of Urological Surgeons, 2002.
9. Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002;20:3206-12.
10. Poon M, Ruckle H, Bamshad BR, et al. Radical retropubic prostatectomy: bladder neck preservation versus reconstruction. J Urol 2000;163:194-8.
11. Guillonneau B, Vallancien G. Laparoscopic radical prostatectomy: the Montsouris technique. J Urol 2000;163:1643-9.
12. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.
13. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-93.
14. Sakr WA, Wheeler TM, Blute M, et al. Staging and reporting of prostate cancer-sampling of the radical prostatectomy specimen. Cancer 1996;78:366-8.
15. Abbou CC, Salomon L, Hoznek A, et al. Laparoscopic radical prostatectomy: preliminary results. Urology 2000;55:630-4.
16. Weldon VE, Tavel FR, Neuwirth H. Continence, potency and morbidity after radical perineal prostatectomy. J Urol 1997;158:1470-5.
17. Frazier HA, Robertson JE, Paulson DF. Radical prastatectomy: the pros and cons of the perineal versus retropubic approach. J Urol 1992;147(3 pt 2):888-90.
18. Eden CG, Cahill D, Vass JA, et al. Laparoscopic radical prostatectomy: the initial UK series. BJU Int 2002;90:876-82.
19. Bollens R, Vanden Bossche M, Roumeguere T, et al. Extraperitoneal laparoscopic radical prostatectomy. Results after 50 cases. Eur Urol 2001;40:65-9.
20. Babaian RJ, Troncoso P, Bhadkamkar VA, et al. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 2001;91:1414-22.
21. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152(5 pt 2):1831-6.
22. Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 1999;49:282-96.
23. Bott SRJ, Thomas K, Foley C, et al. Cancer control, continence and potency after radical prostatectomy - a UK series. British Association of Urological Surgeons annual meeting, Glasgow 2002 (abstract 117).
24. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl Med 2002;347:781-9.
25. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-7.
26. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 1982;128:492-7.
27. Catalona WJ, Carvalhal GF, Mager DE, et al. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999;162:433-8.
28. Walsh PC. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. J Urol 2000;164:242.
29. Salomon L, Anastasiadis AG, Katz R, et al. Urinary continence and erectile function: a prospective evaluation of functional results after radical laparoscopic prostatectomy. Eur Urol 2002;42:338-43.
30. Stamey TA, Villers AA, McNeal JE, et al. Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol 1990;143:1166-72.
31. Horwich A, Wynne C, Nahum A, et al. Conformal radiotherapy at the Royal Marsden Hospital (UK). Int J Radiat Biol 1994;65:117-22.
32. Hanks GE, Hanlon AL, Epstein B, et al. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 2002;54:427-35.
33. Nutting CM, Dearnaley DP. Prostate cancer - the Royal Marsden conformal experience. Front Radiat Ther Oncol 2002;37:196-9.
34. Martinez AA, Gustafson G, Gonzalez J, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:316-27.
35. Blasko JC, Mate T, Sylvester JE, et al. Brachytherapy for carcinoma of the prostate: techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002;12:81-94.
36. 35a Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol 2002;41:427-33.
37. Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999;353:267-72.
38. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75,000 women. Lancet 1992;339:1-15.
39. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
40. Montironi R, Diamanti L, Santinelli A, et al. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study. Pathol Res Pract 1999;195:201-8.
41. Soloway MS, Sharifi R, Wajsman Z, et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995;154(2 pt 1):424-8.
42. Van Poppel H, De Ridder D, Elgamal AA, et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol 1995;154(2 pt 1):429-34.
43. Wieder JA, Soloway MS. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 1998;160:299-315.
44. Soloway MS, et al. Radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in cT2b prostate cancer -24 month results. J Urol 1997;157:160 (abstract 619).
45. Goldenberg S, et al. A randomised trial of neoadjuvant androgen withdrawl therapy prior to radical prostatectomy: 24 month post-treatment PSA results. J Urol 1997;157(part2):92 (abstract 357).
46. Lee HH, Warde P, Jewett MA. Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int 1999;83:438-48.
47. Lawton CA, Winter K, Murray K, et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;49:937-46.
48. See WA, Wirth MP, McLeod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002;168:429-35.
49. Coetzee LJ, Hars V, Paulson DF. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology 1996;47:232-5.
50. Zincke H, Oesterling JE, Blute ML, et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152(5 pt 2):1850-7.
51. Pound CR, Partin AW, Epstein JI, et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
52. Blute ML, Bostwick DG, Seay TM, et al. Pathologic classification of prostate carcinoma: the impact of margin status. Cancer 1998;82:902-8.
53. Valicenti RK, Gomella LG, Ismail M, et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 1999;45:53-8.
54. Cox JD, Gallagher MJ, Hammond EH, et al. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 1999;17:1155.
55. Nudell DM, Grossfeld GD, Weinberg VK, et al. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 1999;54:1049-57.
56. Peschel RE, Robnett TJ, Hesse D, et al. PSA based review of adjuvant and salvage radiation therapy vs observation in postoperative prostate cancer patients. Int J Cancer 2000;90:29-36.
57. Cadeddu JA, Partin AW, De Weese TL. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998;159:173-7.
58. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prastatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341:1781-8.
59. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035-41.
60. Stein A, Smith RB, deKernion JB. Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate. Urology 1992;40:197-200.
61. Koppie TM, Grossfeld GD, Miller D, et al. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor. J Urol 2000;164:81-8.
62. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-8.
63. Albertsen PC, Fryback DG, Storer BE, et al. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995;274:626-31.
64. Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-80.
65. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349:906-10.
66. Hugosson J, Aus G, Becker C, et al. Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden. BJU Int 2000;85:1078-84.
67. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002;347:790-6.